These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 21083052)

  • 61. What is the future of (ultra) high performance liquid chromatography coupled to low and high resolution mass spectrometry for toxicological drug screening?
    Maurer HH
    J Chromatogr A; 2013 May; 1292():19-24. PubMed ID: 22964051
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Addressing the analytical throughput challenges in ADME screening using rapid ultra-performance liquid chromatography/tandem mass spectrometry methodologies.
    Plumb RS; Potts WB; Rainville PD; Alden PG; Shave DH; Baynham G; Mazzeo JR
    Rapid Commun Mass Spectrom; 2008 Jul; 22(14):2139-52. PubMed ID: 18543375
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Drug screening of pharmaceutical discovery compounds by micro-size exclusion chromatography/mass spectrometry.
    Wabnitz PA; Loo JA
    Rapid Commun Mass Spectrom; 2002; 16(2):85-91. PubMed ID: 11754252
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Principles and applications of LC-MS in new drug discovery.
    Korfmacher WA
    Drug Discov Today; 2005 Oct; 10(20):1357-67. PubMed ID: 16253874
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Evaluation of LC-MS for the analysis of cleaning verification samples.
    Simmonds EL; Lough WJ; Gray MR
    J Pharm Biomed Anal; 2006 Feb; 40(3):631-8. PubMed ID: 16311001
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Phase-0/microdosing studies using PET, AMS, and LC-MS/MS: a range of study methodologies and conduct considerations. Accelerating development of novel pharmaceuticals through safe testing in humans - a practical guide.
    Burt T; John CS; Ruckle JL; Vuong LT
    Expert Opin Drug Deliv; 2017 May; 14(5):657-672. PubMed ID: 27564533
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Development of a low volume plasma sample precipitation procedure for liquid chromatography/tandem mass spectrometry assays used for drug discovery applications.
    Xu X; Zhou Q; Korfmacher WA
    Rapid Commun Mass Spectrom; 2005; 19(15):2131-6. PubMed ID: 15988723
    [TBL] [Abstract][Full Text] [Related]  

  • 68. In vivo metabolite detection and identification in drug discovery via LC-MS/MS with data-dependent scanning and postacquisition data mining.
    Triolo A; Altamura M; Dimoulas T; Guidi A; Lecci A; Tramontana M
    J Mass Spectrom; 2005 Dec; 40(12):1572-82. PubMed ID: 16320289
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A simple liquid-liquid extraction with hexane for low-picogram determination of drugs and their metabolites in plasma by high-performance liquid chromatography with positive ion electrospray tandem mass spectrometry.
    Xia YQ; Whigan DB; Jemal M
    Rapid Commun Mass Spectrom; 1999; 13(15):1611-21. PubMed ID: 10421903
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Investigation of matrix effects in bioanalytical high-performance liquid chromatography/tandem mass spectrometric assays: application to drug discovery.
    Mei H; Hsieh Y; Nardo C; Xu X; Wang S; Ng K; Korfmacher WA
    Rapid Commun Mass Spectrom; 2003; 17(1):97-103. PubMed ID: 12478560
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction.
    Unger M; Frank A
    Rapid Commun Mass Spectrom; 2004; 18(19):2273-81. PubMed ID: 15384148
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Rapid automated screening, identification and quantification of organic micro-contaminants and their main transformation products in wastewater and river waters using liquid chromatography-quadrupole-time-of-flight mass spectrometry with an accurate-mass database.
    Gómez MJ; Gómez-Ramos MM; Malato O; Mezcua M; Férnandez-Alba AR
    J Chromatogr A; 2010 Nov; 1217(45):7038-54. PubMed ID: 20926086
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Development, validation and transfer into a factory environment of a liquid chromatography tandem mass spectrometry assay for the highly neurotoxic impurity FMTP (4-(4-fluorophenyl)-1-methyl-1,2,3,6-tetrahydropyridine) in paroxetine active pharmaceutical ingredient (API).
    Borman PJ; Chatfield MJ; Crowley EL; Eckers C; Elder DP; Francey SW; Laures AM; Wolff JC
    J Pharm Biomed Anal; 2008 Dec; 48(4):1082-9. PubMed ID: 18835674
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Liquid chromatography/tandem mass spectrometric bioanalysis using normal-phase columns with aqueous/organic mobile phases - a novel approach of eliminating evaporation and reconstitution steps in 96-well SPE.
    Naidong W; Shou WZ; Addison T; Maleki S; Jiang X
    Rapid Commun Mass Spectrom; 2002; 16(20):1965-75. PubMed ID: 12362389
    [TBL] [Abstract][Full Text] [Related]  

  • 75. AutoScan: an automated workstation for rapid determination of mass and tandem mass spectrometry conditions for quantitative bioanalytical mass spectrometry.
    Whalen KM; Rogers KJ; Cole MJ; Janiszewski JS
    Rapid Commun Mass Spectrom; 2000; 14(21):2074-9. PubMed ID: 11085421
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Validation of bioanalytical LC-MS/MS assays: evaluation of matrix effects.
    Van Eeckhaut A; Lanckmans K; Sarre S; Smolders I; Michotte Y
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Aug; 877(23):2198-207. PubMed ID: 19179125
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Are multimetabolite methods fit-for-purpose for supporting toxicology studies?
    Smith G
    Bioanalysis; 2011 Dec; 3(24):2701-4. PubMed ID: 22185267
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Capsule review on bioanalytical method transfer: opportunities and challenges for chromatographic methods.
    Lin ZJ; Li W; Weng N
    Bioanalysis; 2011 Jan; 3(1):57-66. PubMed ID: 21175367
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Regulatory considerations for development of bioanalytical assays for biotechnology products.
    Swann PG; Shapiro MA
    Bioanalysis; 2011 Mar; 3(6):597-603. PubMed ID: 21417729
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Pharmacokinetic applications of microdevices and microsampling techniques.
    Musteata FM
    Bioanalysis; 2009 Apr; 1(1):171-85. PubMed ID: 21083195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.